Global X Genomics & Biotechnology UCITS ETFGlobal X Genomics & Biotechnology UCITS ETFGlobal X Genomics & Biotechnology UCITS ETF

Global X Genomics & Biotechnology UCITS ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪6.40 M‬GBP
Fund flows (1Y)
‪3.04 M‬GBP
Dividend yield (indicated)
Discount/Premium to NAV
−0.04%
Shares outstanding
‪1.10 M‬
Expense ratio
0.60%

About Global X Genomics & Biotechnology UCITS ETF


Issuer
Mirae Asset Global Investments Co., Ltd.
Brand
Global X
Inception date
Nov 2, 2021
Index tracked
Solactive Genomics v2 Index - Benchmark TR Net
Replication method
Physical
Management style
Passive
Dividend treatment
Capitalizes
Primary advisor
Carne Global Fund Managers (Ireland) Ltd.
ISIN
IE00BM8R0N95
The Funds investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index

Broaden your horizons with more funds linked to GNOG via country, focus, and more.

Classification


Asset Class
Equity
Category
Sector
Focus
Theme
Niche
Genomic advancements
Strategy
Vanilla
Geography
Global
Weighting scheme
Market cap
Selection criteria
Market cap
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Health Services
Stock breakdown by region
79%16%3%
Top 10 holdings
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
GNOG trades at 4.2550 GBP today, its price has risen 0.53% in the past 24 hours. Track more dynamics on GNOG price chart.
GNOG net asset value is 4.29 today — it's risen 3.67% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
GNOG assets under management is ‪6.40 M‬ GBP. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
GNOG price has risen by 6.14% over the last month, and its yearly performance shows a −26.69% decrease. See more dynamics on GNOG price chart.
NAV returns, another gauge of an ETF dynamics, showed a −10.13% decrease in three-month performance and has decreased by −24.05% in a year.
GNOG fund flows account for ‪3.04 M‬ GBP (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
GNOG invests in stocks. See more details in our Analysis section.
GNOG expense ratio is 0.60%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, GNOG isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, GNOG technical analysis shows the sell rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating GNOG shows the sell signal. See more of GNOG technicals for a more comprehensive analysis.
No, GNOG doesn't pay dividends to its holders.
GNOG trades at a premium (0.04%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
GNOG shares are issued by Mirae Asset Global Investments Co., Ltd.
GNOG follows the Solactive Genomics v2 Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Nov 2, 2021.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.